Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report
January 2022
in “
SSRN Electronic Journal
”
Studysummary In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research. Our plain-language summary of this paper — not a Tressless recommendation.
This case report described a 68-year-old man with muscle-invasive bladder cancer (MIBC) and severe renal insufficiency who was treated with neoadjuvant therapy using gemcitabine and Disitamab Vedotin (DV) due to intolerance to platinum-based regimens. The patient received three cycles of treatment, resulting in a significant reduction of lesions without any aggravation in blood test results or significant abnormal symptoms. Postoperative analysis showed increased HER2 expression. The study concluded that gemcitabine combined with DV was effective and safe for this patient, suggesting the need for further clinical studies with more patients to validate these findings.
